CJC-1295 in Progresso — GHRH Analog Research Guide
CJC-1295 research guide for Progresso. Covers DAC vs no-DAC forms, half-life differences, purity testing, and how to source quality CJC-1295 for research.
For anyone in Progresso looking to source CJC-1295, the foundational reality is that this compound is distributed via specialist online vendors. The practical takeaway for Progresso researchers: sourcing CJC-1295 comes down completely to vendor quality evaluation, not geography — and the evaluation methodology is universal across all locations. The key verification criteria for CJC-1295 are HPLC purity ≥98%, molecular identity verified through mass spectrometry, and a bacterial endotoxin panel — all documented in a batch-specific Certificate of Analysis. Use this guide to evaluate CJC-1295 vendors rigorously — the framework here are universal across all research contexts.
CJC-1295 Mechanisms Explained
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: CJC-1295 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Progresso comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
How to Evaluate CJC-1295 Vendors
The first step for any Progresso researcher sourcing CJC-1295 is finding vendors with verified community track records — organic rankings are no guide to actual CJC-1295 quality. A COA for CJC-1295 should include: HPLC purity percentage with the full chromatographic trace, mass spectrometry data verifying the correct molecular weight, endotoxin test results, and a residual solvent panel — all specific to the lot you receive. For Progresso researchers evaluating unfamiliar vendors: a modest first purchase to test the product before placing larger orders is the accepted approach among experienced researchers. For Progresso researchers making a first CJC-1295 purchase: verify the vendor against this framework, start with a modest quantity, and verify batch traceability on arrival before use.
Order CJC-1295 — ships to Progresso
COA-verified · International tracking · Research grade
Research compound status for CJC-1295 means the safety evidence is drawn from animal studies, in-vitro work, and limited human observations — rather than the large-scale clinical data that informs approved drug safety. Lyophilised CJC-1295 should be placed in the freezer at −20°C straight away; avoid repeatedly thawing and refreezing reconstituted peptide by preparing small aliquots before storage. Bacterial endotoxin contamination is the most serious safety risk unique to this class of compound — verify endotoxin testing is included in the batch-specific COA before any injectable research application. PubMed and bioRxiv are the primary literature resources for CJC-1295 research; favour indexed journal publications over preprints over case reports or anecdotal evidence.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
